| Literature DB >> 32328653 |
Patrick Y Wen1, Michael Weller2, Eudocia Quant Lee1, Brian M Alexander1, Jill S Barnholtz-Sloan3, Floris P Barthel4, Tracy T Batchelor5, Ranjit S Bindra6, Susan M Chang7, E Antonio Chiocca8, Timothy F Cloughesy9, John F DeGroot10, Evanthia Galanis11, Mark R Gilbert12, Monika E Hegi13, Craig Horbinski14, Raymond Y Huang15, Andrew B Lassman16, Emilie Le Rhun17, Michael Lim18, Minesh P Mehta19, Ingo K Mellinghoff20, Giuseppe Minniti21, David Nathanson22, Michael Platten23, Matthias Preusser24, Patrick Roth2, Marc Sanson25, David Schiff26, Susan C Short27, Martin J B Taphoorn28, Joerg-Christian Tonn29, Jonathan Tsang22, Roel G W Verhaak4, Andreas von Deimling30, Wolfgang Wick31, Gelareh Zadeh32, David A Reardon1, Kenneth D Aldape33, Martin J van den Bent34.
Abstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.Entities:
Keywords: clinical trials; diagnosis; glioblastoma; therapy
Mesh：
Substances：
Year: 2020 PMID： 32328653 PMCID： PMC7594557 DOI： 10.1093/neuonc/noaa106
Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300